Please assess the completion status of the following clinical trial:

Trial Title: Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Biopsy-confirmed diagnosis of 1 of the following:~  * Mild to severe dysplasia~ * Carcinoma in situ (CIS) of the oral cavity~    * Carcinoma must be less than 3mm thick~ * Stage I (T1) squamous cell carcinoma of the oral cavity~* Recurrent or primary disease~* No T2 or greater squamous cell carcinoma, exophytic CIS, or dysplasia lesions~PATIENT CHARACTERISTICS:~* ECOG performance status 0-2~* Total bilirubin ≤ 2.0 mg/dL~* Creatinine ≤ 2.0 mg/dL~* Alkaline phosphatase ≤ 3 times the upper limit of normal (ULN)~* SGOT ≤ 3 times ULN~* Not pregnant~* Fertile patients must use effective contraception~* No porphyria or hypersensitivity to porphyrin or porphyrin-like compounds~PRIOR CONCURRENT THERAPY:~* Prior therapy of any type allowed~* More than 4 weeks since prior and no concurrent chemotherapy or radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Treatment (PDT) (Type: EXPERIMENTAL): Patients undergo PDT comprising HPPH IV over 1 hour on day 1 followed by laser light treatment to the tumor bed on day 2. Treatment may repeat every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).